喉鳞状细胞癌MTS1／p16基因纯合子缺失的检测

为探讨MTS1／p16基因在喉癌中纯合子缺失情况及其与喉癌生物学行为的关系,本研究用比较PCR技术对59例喉鳞状细胞癌（LSCC）MTS1／p16基因纯合子缺失进行检测。剔除3例不可比样本,9／56 LSCC有MTS1／p16基因纯合子缺失,缺失率为16．07％。MTS1／p16基因纯合子缺失与LSCC病理分级无关;LSCC晚期（Ⅲ-Ⅳ）期的MTS1／p16基因纯合子缺失率（36．84％）明显高于早期（Ⅰ-Ⅱ期）肿瘤（5．4％）,P＜0．01,显示MTS1／p16基因纯合子缺失与LSCC的自然病程有关。认为MTS1／p16基因纯合子缺失是LSCC发生发展过程中的分子机制之一,可能与LSCC的恶性发展有关。

Homozygous deletions of MTS1/p16 gene in laryngeal squamous cell carcinoma

To study the status of homozygous deletions of MTS1/p16 gene in squamous cell carcinoma of the larynx (LSCC) and to discuss the relations of homozygous deletions to the pathological grade and clinical stage of the tumor,Fifty-nine primary LSCC were examined for homozygous deletions of the MTS1/p16 gene by comparative PCR.Three specimens were eliminated for being incapable of comparison with others.Homozygous deletions of the MTS1/p16 gene were found in 9 of 56 tumors (16.07%).The rates of homozygous deletions of MTS1/p16 gene in well,medially,poorly differentiated tumors were 17.24%(5/29),11.76%(2/17),and 20.00%(2/10) respectively.There had no significant difference in various pathological grades of tumors.Homozygous deletions rates of tumors in stagesⅠ～Ⅱand in stagesⅢ～Ⅳwere 5.41% (2/37) and 36.84%(7/19) respectively.The rate of homozygous deletions in stages Ⅲ～Ⅳtumors was significantly higher than that in stagesⅠ～Ⅱ(P＜0.01).Homozygous deletions of the MTS1/p16 gene were correlated well with clinical stages.Our data suggested that homozygous deletions of MTS1/p16 gene might be one of the genetic events in the development of the tumor and might play a role in malignant progression of LSCC.